Edition:
India

ACADIA Pharmaceuticals Inc (ACAD.OQ)

ACAD.OQ on NASDAQ Stock Exchange Global Select Market

15.20USD
25 Apr 2018
Change (% chg)

$-4.27 (-21.93%)
Prev Close
$19.47
Open
$19.40
Day's High
$20.03
Day's Low
$14.52
Volume
3,812,737
Avg. Vol
655,449
52-wk High
$41.20
52-wk Low
$14.52

Chart for

About

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease... (more)

Overall

Beta: 3.36
Market Cap(Mil.): $2,484.06
Shares Outstanding(Mil.): 124.70
Dividend: --
Yield (%): --

Financials

FDA says reviewing Acadia's Parkinson's medication, shares fall

WASHINGTON The U.S. Food and Drug Administration said on Wednesday it was reviewing Acadia Pharmaceuticals' Parkinson's medication, the only approved drug used to treat hallucinations and delusions associated with the disease.

1:25am IST

FDA says reviewing Acadia's Parkinson's medication, shares fall

WASHINGTON, April 25 The U.S. Food and Drug Administration said on Wednesday it was reviewing Acadia Pharmaceuticals' Parkinson's medication, the only approved drug used to treat hallucinations and delusions associated with the disease.

1:23am IST

BRIEF-Acadia Pharma Q4 Loss Per Share $0.55

* ACADIA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

28 Feb 2018

BRIEF-Acadia Pharmaceuticals posts Q3 loss of $0.53 per share

* Acadia Pharmaceuticals reports third quarter 2017 financial results

08 Nov 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.68 -0.38
Eli Lilly And Co (LLY.N) $81.14 +1.05
Eisai Co., Ltd (4523.T) ¥7,295 -69.00

Earnings vs. Estimates